589A94F8-2432-4D6D-94EB-B327ECA291AF
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 39.71747700394218
- age_years
- 34
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.569
- G2M_CHECKPOINT+0.431
- TGF_BETA_SIGNALING+0.410
- MITOTIC_SPINDLE+0.409
- WNT_BETA_CATENIN_SIGNALING+0.345
- E2F_TARGETS+0.307
- UV_RESPONSE_DN+0.286
- HEDGEHOG_SIGNALING+0.276
- PROTEIN_SECRETION+0.274
- CHOLESTEROL_HOMEOSTASIS+0.245
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.402
- ANGIOGENESIS-0.360
- COAGULATION-0.359
- ALLOGRAFT_REJECTION-0.343
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.326
- MYOGENESIS-0.322
- KRAS_SIGNALING_DN-0.305
- PANCREAS_BETA_CELLS-0.282
- IL2_STAT5_SIGNALING-0.244
- INFLAMMATORY_RESPONSE-0.236
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934805 | — | — | 0.911 |
| 2 | E6090BC6-D29D-4401-990A-251930CC6853 | — | — | 0.899 |
| 3 | SRR934849 | — | — | 0.898 |
| 4 | 4A2E75AE-A92F-4497-9253-64AC42CFA745 | — | — | 0.891 |
| 5 | 2DA298A9-AB20-4F9D-B83F-C7FC0679F889 | — | — | 0.886 |
| 6 | SRR934728 | — | — | 0.883 |
| 7 | 4549956C-8D25-4B37-894C-E82D5C7684F0 | — | — | 0.881 |
| 8 | SRR934858 | — | — | 0.881 |
| 9 | SRR934986 | — | — | 0.880 |
| 10 | SRR934758 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.569 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.431 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.409 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.345 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.307 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.286 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.276 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.274 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.245 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.183 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.146 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.134 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.088 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.077 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.063 | Inavolisib | — uncovered |
| PEROXISOME | 0.043 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.033 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.019 | Temsirolimus | — uncovered |